CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated biologics, today announced the appointment of Sean McCarthy, D.Phil., as chief executive officer. Dr. McCarthy joined CytomX in January 2011 as its chief business officer and will lead the company as it advances its ProbodyTM platform. He replaces Nancy Stagliano, Ph.D., a co-founder of CytomX and co-inventor of its foundational technology platform. Dr. Stagliano will join CytomX’s scientific advisory board and serve as a consultant to the company.
